This randomized controlled trial addresses the question of whether overt type II diabetes mellitus can be prevented in patients with existing impaired glucose tolerance by inhibiting the renin-angiotensin-aldosterone axis. The results suggest that early RAAS blockade can significantly decrease the likelihood of diabetes development in predisposed patients, but that the cumulative risk of cardiovascular outcomes does not change in either group.

**************************************
Time Required (estimated): 35 minutes
Title: Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
Citation: New England Journal of Medicine 2010; doi 10.1056/NEJMoa1001121
Date Created: 2010
Revisions: None Indicated
Disclaimers: Novartis Pharma (see page 12 of the article)
Resource Type: Text
Other: Recommended by Paul Bolin, MD
Recommend to a Colleague/Friend
**************************************

Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.



Transparent Peer Review
Your reviews are anonymous

GD Star Rating
loading...


To learn more about our 6-point transparent peer review system, click here



Blocking Renin-Angiotensin-Aldosterone axis to Prevent Type II Diabetes Mellitus: The NAVIGATOR Study , 1.0 out of 10 based on 1 rating
Share

Comments

  • Nephrology On-Demand Plus


    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


    Available_on_the_App_Store_(black)

  • Kidney Konnection


    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription
More in Diabetic Nephropathy, General Nephrology (154 of 212 articles)